Entity Central Index Key
Total amount of revenue recognized for license and development services under the collaboration agreement as of a given date.
Cover [Abstract]
Document Type
Document Type
Amendment Flag
Amendment Flag
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Trading Symbol
Trading Symbol
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Well Known Seasoned Issuer
Entity Current Reporting Status
Entity Current Reporting Status
Entity Voluntary Filers
Entity Voluntary Filers
Entity Filer Category
Entity Filer Category
Entity Shell Company
Entity Shell Company
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Interactive Data Current
Entity Interactive Data Current
Title of 12(b) Security
Security12b Title
Security Exchange Name
Security Exchange Name
Entity File Number
Entity File Number
Entity Incorporation, State or Country Code
Entity Incorporation State Country Code
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address Address Line1
Entity Address, City or Town
Entity Address City Or Town
Entity Address, State or Province
Entity Address State Or Province
Entity Address, Postal Zip Code
Entity Address Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Entity Common Stock, Shares Outstanding
Entity Common Stock Shares Outstanding
Entity Public Float
Entity Public Float
Document Annual Report
Document Annual Report
Document Transition Report
Document Transition Report
ICFR Auditor Attestation Flag
Icfr Auditor Attestation Flag
Restricted time deposits noncurrent.
Equity method investment in unconsolidated variable interest entity.
Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.
Statement Of Financial Position [Abstract]
Assets
Assets [Abstract]
Current assets:
Assets Current [Abstract]
Cash and cash equivalents
Cash And Cash Equivalents At Carrying Value
Short-term investments
Short Term Investments
Accounts receivable, net ($4,127 and $4,845 from a related party)
Accounts Receivable Net Current
Inventories
Inventory Net
Prepaid expenses and other current assets ($889 and $125,210 from related parties)
Prepaid Expense And Other Assets Current
Total current assets
Assets Current
Restricted time deposits
Restricted Time Deposits Noncurrent
Long-term investments
Long Term Investments
Property and equipment, net
Property Plant And Equipment Net
Finance lease right-of-use assets
Finance Lease Right Of Use Asset
Equity method investment in unconsolidated variable interest entity
Equity Method Investment In Unconsolidated Variable Interest Entity
Other assets
Other Assets Noncurrent
Total assets
Assets
Liabilities, stockholders’ equity and non-controlling interests
Liabilities And Stockholders Equity [Abstract]
Current liabilities:
Liabilities Current [Abstract]
Accounts payable ($1,118 and $0 to a related party)
Accounts Payable Current
Accrued and other current liabilities ($24 and $36,883 to a related party)
Accrued Liabilities And Other Liabilities
Deferred revenue ($2,907 and $249 to a related party)
Contract With Customer Liability Current
Finance lease liabilities, current
Finance Lease Liability Current
Total current liabilities
Liabilities Current
Product development obligations
Accrued Product Development Costs
Deferred revenue, net of current ($4,636 and $125 to a related party)
Contract With Customer Liability Noncurrent
Finance lease liabilities, non-current
Finance Lease Liability Noncurrent
Other long-term liabilities
Other Liabilities Noncurrent
Total liabilities
Liabilities
Commitments and Contingencies (Note 9)
Commitments And Contingencies
Stockholders’ equity:
Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019
Preferred Stock Value
Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2020 and 2019; 91,441 and 87,657 shares issued and outstanding at December 31, 2020 and 2019
Common Stock Value
Additional paid-in capital
Additional Paid In Capital
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income Loss Net Of Tax
Accumulated deficit
Retained Earnings Accumulated Deficit
Total stockholders’ equity
Stockholders Equity
Non-controlling interests
Minority Interest
Total equity
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
Total liabilities, stockholders’ equity and non-controlling interests
Liabilities And Stockholders Equity
Due to related parties deferred revenue current.
Due to related parties deferred revenue noncurrent.
Accounts receivable from related party
Accounts Receivable Related Parties Current
Prepaid expenses and other current assets from related parties
Due From Related Parties Current
Accounts payable to related party
Accounts Payable Related Parties Current
Accrued and other current liabilities to related party
Due To Related Parties Current
Deferred revenue current to related party
Due To Related Parties Deferred Revenue Current
Deferred revenue non-current to related party
Due To Related Parties Deferred Revenue Noncurrent
Preferred stock, par value
Preferred Stock Par Or Stated Value Per Share
Preferred stock, shares authorized
Preferred Stock Shares Authorized
Preferred stock, shares issued
Preferred Stock Shares Issued
Preferred stock, shares outstanding
Preferred Stock Shares Outstanding
Common stock, par value
Common Stock Par Or Stated Value Per Share
Common stock, shares authorized
Common Stock Shares Authorized
Common stock, shares issued
Common Stock Shares Issued
Common stock, shares outstanding
Common Stock Shares Outstanding
Cost of goods and services sold operating expense.
Unconsolidated variable interest entity investment loss.
Interest and other net.
Income Statement [Abstract]
Statement [Table]
Statement [Table]
Product and Service
Product Or Service [Axis]
Product and Service
Products And Services [Domain]
License Revenue [Member]
License [Member]
Development and other revenue.
Development and Other Revenue [Member]
Development And Other Revenue [Member]
Product Revenue, Net [Member]
Product [Member]
Drug product revenue.
Drug Product Revenue [Member]
Drug Product Revenue [Member]
Statement [Line Items]
Statement [Line Items]
Revenue:
Revenue From Contract With Customer [Abstract]
Total revenue
Revenue From Contract With Customer Excluding Assessed Tax
Operating costs and expenses:
Operating Costs And Expenses [Abstract]
Cost of goods sold
Cost Of Goods And Services Sold Operating Expense
Cost, Product and Service [Extensible List]
Type Of Cost Good Or Service Extensible List
Research and development
Research And Development Expense
Selling, general and administrative
Selling General And Administrative Expense
Total operating costs and expenses
Operating Expenses
Loss from operations
Operating Income Loss
Interest and other, net
Interest And Other Net [Abstract]
Interest expense
Interest Expense
Investment loss in unconsolidated variable interest entity
Unconsolidated Variable Interest Entity Investment Loss
Interest income and other, net
Interest And Other Income
Total interest and other, net
Interest Income Expense Nonoperating Net
Loss before income taxes
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
Provision for income taxes
Income Tax Expense Benefit
Net loss
Net Income Loss
Net loss per share - basic and diluted
Earnings Per Share Basic And Diluted
Weighted average number of common shares used to calculate net loss per share - basic and diluted
Weighted Average Number Of Share Outstanding Basic And Diluted
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period.
Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.
Product revenue from a related party.
Collaborative Arrangement and Arrangement Other than Collaborative
Type Of Arrangement [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Arrangements And Nonarrangement Transactions [Member]
Astellas agreements.
Astellas Agreement [Member]
Astellas Collaboration Agreement [Member]
License and milestone revenue from a related party
License Fees And Milestones Revenue
Collaboration services and other revenue from a related party
Collaboration Services And Other Revenue
Product revenue from a related party
Product Revenue
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)
Other comprehensive income (loss):
Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]
Foreign currency translation adjustments (Note 2)
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
Available-for-sale investments:
Other Comprehensive Income Available For Sale Securities Adjustment Net Of Tax Period Increase Decrease [Abstract]
Unrealized gain (loss) on investments, net of tax effect
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
Other comprehensive income (loss), net of taxes
Other Comprehensive Income Loss Net Of Tax
Comprehensive income (loss)
Comprehensive Income Net Of Tax
Shares issued from stock plans net of payroll taxes paid shares.
Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.
Warrant exercised during period shares.
Warrants exercised during period value.
Statement Of Stockholders Equity [Abstract]
Equity Components
Statement Equity Components [Axis]
Equity Component
Equity Component [Domain]
Common Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid In Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Retained Earnings [Member]
Noncontrolling Interests [Member]
Noncontrolling Interest [Member]
Cumulative Effect, Period of Adoption
Cumulative Effect Period Of Adoption [Axis]
Cumulative Effect, Period of Adoption
Cumulative Effect Period Of Adoption [Domain]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Cumulative Effect Period Of Adoption Adjustment [Member]
Accounting Standards Update
Adjustments For New Accounting Pronouncements [Axis]
Accounting Standards Update
Type Of Adoption [Member]
ASU 2016-02 [Member]
Accounting Standards Update201602 [Member]
ASU 2018-02 [Member]
Accounting Standards Update201802 [Member]
ASU 2016-01 [Member]
Accounting Standards Update201601 [Member]
Balance
Balance, Shares
Shares Outstanding
Change in unrealized gain or loss on investments
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
Foreign currency translation adjustments
Adjustment to issuance costs for Follow-on Offerings
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
Shares issued from stock plans, net of payroll taxes paid
Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid
Shares issued from stock plans, net of payroll taxes paid, Shares
Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares
Warrants exercised
Warrants Exercised During Period Value
Warrants exercised, Shares
Warrant Exercised During Period Shares
Stock-based compensation
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Balance
Balance, Shares
Unrealized loss (gain) on equity investments.
Investment loss in unconsolidated variable interest entity.
Increase decrease in lease obligations.
Increase (decrease) in accrued interest for finance lease liabilities.
Payment made for investment in unconsolidated variable interest entity.
Proceeds from equity transfer of unconsolidated variable interest entity.
Payments to acquire available for sale securities and term deposit.
Repayments of finance lease liabilities.
Statement Of Cash Flows [Abstract]
Operating activities
Net Cash Provided By Used In Operating Activities [Abstract]
Net loss
Profit Loss
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Depreciation
Depreciation
Amortization of finance lease right-of-use assets
Finance Lease Right Of Use Asset Amortization
Net accretion of discount on investments
Accretion Amortization Of Discounts And Premiums Investments
Unrealized loss (gain) on equity investments
Unrealized Loss Gain On Equity Investments
Investment loss in unconsolidated variable interest entity
Investment Loss In Unconsolidated Variable Interest Entity
Loss (gain) on disposal of property and equipment
Gain Loss On Disposition Of Assets
Stock-based compensation
Share Based Compensation
Realized foreign currency gain
Foreign Currency Transaction Gain Loss Realized
Realized loss (gain) on sales of available-for-sale securities
Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments
Changes in operating assets and liabilities:
Increase Decrease In Operating Capital [Abstract]
Accounts receivable, net ($718, $42,365 and $(43,486) from a related party)
Increase Decrease In Accounts Receivable
Inventories
Increase Decrease In Inventories
Prepaid expenses and other current assets ($124,321, $(125,210) and $0 from a related party)
Increase Decrease In Prepaid Deferred Expense And Other Assets
Other assets
Increase Decrease In Other Operating Assets
Accounts payable ($1,118, $0 and $0 from a related party)
Increase Decrease In Accounts Payable
Accrued and other liabilities ($(36,859), $36,439 and $172 from a related party)
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
Deferred revenue ($7,169, $(3,137) and $(3,908) from a related party)
Increase Decrease In Contract With Customer Liability
Lease obligations
Increase Decrease In Lease Obligations
Accrued interest for finance lease liabilities
Increase Decrease In Accrued Interest For Finance Lease Liabilities
Other long-term liabilities
Increase Decrease In Other Noncurrent Liabilities
Net cash provided by (used in) operating activities
Net Cash Provided By Used In Operating Activities
Investing activities
Net Cash Provided By Used In Investing Activities [Abstract]
Purchases of property and equipment
Payments To Acquire Property Plant And Equipment
Payment made for investment in unconsolidated variable interest entity
Payment Made For Investment In Unconsolidated Variable Interest Entity
Proceeds from equity transfer of unconsolidated variable interest entity
Proceeds From Equity Transfer Of Unconsolidated Variable Interest Entity
Proceeds from sale of property and equipment
Proceeds From Sale Of Property Plant And Equipment
Purchases of available-for-sale securities and term deposit
Payments To Acquire Available For Sale Securities And Term Deposit
Proceeds from sales of available-for-sale securities
Proceeds From Sale Of Available For Sale Securities
Proceeds from maturities of investments
Proceeds From Sale Maturity And Collections Of Investments
Net cash provided by (used in) investing activities
Net Cash Provided By Used In Investing Activities
Financing activities
Net Cash Provided By Used In Financing Activities [Abstract]
Borrowings under capital lease obligations
Proceeds From Long Term Capital Lease Obligations
Repayments of capital lease obligations
Repayments Of Long Term Capital Lease Obligations
Repayments of finance lease liabilities
Repayments Of Finance Lease Liabilities
Repayments of lease obligations
Repayments Of Debt And Capital Lease Obligations
Cash paid for payroll taxes on restricted stock unit releases
Payments Related To Tax Withholding For Share Based Compensation
Proceeds from issuance of common stock
Proceeds From Issuance Of Common Stock
Net cash provided by (used in) financing activities
Net Cash Provided By Used In Financing Activities
Effect of exchange rate change on cash and cash equivalents
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
Net increase (decrease) in cash and cash equivalents
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Total cash and cash equivalents at beginning of period
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
Total cash and cash equivalents at end of period
Supplemental cash flow information:
Supplemental Cash Flow Information [Abstract]
Interest payments
Interest Paid Net
Balance in accounts payable and accrued liabilities related to purchases of property and equipment
Capital Expenditures Incurred But Not Yet Paid
Deferred offering costs recorded in accounts payable and accrued liabilities
Liabilities Assumed1
Increase decrease in prepaid expenses and other current assets related parties.
Increase decrease in accounts payable from related party.
Accounts receivable from related party
Increase Decrease In Accounts Receivable Related Parties
Prepaid expenses and other current assets from related party
Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties
Accounts payable from related party
Increase Decrease In Accounts Payable From Related Party
Accrued and other liabilities from related party
Increase Decrease In Accounts Payable Related Parties
Deferred revenue from related party
Increase Decrease In Deferred Revenue
Documents Incorporated by Reference
Documents Incorporated By Reference [Text Block]
Organization Consolidation And Presentation Of Financial Statements [Abstract]
The Company
Business Description And Basis Of Presentation [Text Block]
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Acquisition and variable interest entity.
Acquisition and variable interest entity abstract.
Acquisition And Variable Interest Entity [Abstract]
Acquisition and Variable Interest Entity
Acquisition And Variable Interest Entity [Text Block]
Collaborative arrangement and revenues.
Collaboration Agreements and Revenues
Collaborative Arrangement And Revenues Disclosure [Text Block]
Fair Value Disclosures [Abstract]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Leases [Abstract]
Leases
Leases Of Lessee Disclosure [Text Block]
Balance Sheet Components
Supplemental Balance Sheet Disclosures [Text Block]
Product development obligation disclosure.
Debt Disclosure [Abstract]
Product Development Obligations
Product Development Obligations Disclosure [Text Block]
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies
Commitments And Contingencies Disclosure [Text Block]
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity and Stock-based Compensation
Shareholders Equity And Share Based Payments [Text Block]
Earnings Per Share [Abstract]
Net Loss Per Share
Earnings Per Share [Text Block]
Compensation And Retirement Disclosure [Abstract]
FibroGen, Inc. 401(k) Plan
Pension And Other Postretirement Benefits Disclosure [Text Block]
Income Tax Disclosure [Abstract]
Income Taxes
Income Tax Disclosure [Text Block]
Related Party Transactions [Abstract]
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Segment Reporting [Abstract]
Segment and Geographic Information
Segment Reporting Disclosure [Text Block]
Valuation And Qualifying Accounts [Abstract]
Schedule II - Valuation and Qualifying Accounts
Schedule Of Valuation And Qualifying Accounts Disclosure [Text Block]
Basis of Presentation
Basis Of Accounting Policy Policy [Text Block]
Variable Interest Entity
Consolidation Variable Interest Entity Policy
Foreign Currency Translation
Foreign Currency Transactions And Translations Policy [Text Block]
Use of Estimates
Use Of Estimates
Concentration of Credit Risk
Concentration Risk Credit Risk
Other Risks and Uncertainties.
Other Risks and Uncertainties
Other Risks And Uncertainties Policy [Text Block]
Cash and cash equivalents and restricted time deposits policy.
Cash, Cash Equivalents and Restricted Time Deposits
Cash And Cash Equivalents And Restricted Time Deposits Policy Policy [Text Block]
Investments
Investment Policy [Text Block]
Fair Value of Financial Instruments
Fair Value Of Financial Instruments Policy
Trade Accounts Receivable
Trade And Other Accounts Receivable Policy
Credit Losses – Available-for-sale Debt Securities
Credit Loss Financial Instrument Policy [Text Block]
Inventories
Inventory Policy [Text Block]
Property and Equipment
Property Plant And Equipment Policy [Text Block]
Leases
Lessee Leases Policy [Text Block]
Impairment of Long-Lived Assets
Impairment Or Disposal Of Long Lived Assets Policy [Text Block]
Revenue Recognition
Revenue Recognition Policy [Text Block]
Research and Development Expenses
Research And Development Expense Policy
Clinical trial accrual.
Clinical Trial Accruals
Clinical Trial Accrual Policy [Text Block]
Selling, General and Administrative Expenses
Selling General And Administrative Expenses Policy [Text Block]
Income Taxes
Income Tax Policy [Text Block]
Stock-Based Compensation
Share Based Compensation Option And Incentive Plans Policy
Comprehensive Income (Loss)
Comprehensive Income Policy Policy [Text Block]
Recently issued and adopted accounting guidance.
Recently Issued and Adopted Accounting Guidance
Recently Issued And Adopted Accounting Guidance Policy [Text Block]
Recently issued accounting guidance not yet adopted.
Recently Issued Accounting Guidance Not Yet Adopted
Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block]
Collaborative arrangement and revenues.
Collaboration Arrangements and Revenues
Collaborative Arrangement And Revenues Policy [Text Block]
Product revenue policy.
Product Revenue, Net
Product Revenue Policy Policy [Text Block]
Drug product revenue.
Drug Product Revenue
Drug Product Revenue Policy [Text Block]
Other revenues policy.
Other Revenues
Other Revenues Policy [Text Block]
Deferred Revenue
Revenue From Contract With Customer Policy [Text Block]
Fair Value Measurements
Fair Value Measurement Policy Policy [Text Block]
Schedule of Significant Balance of Accounts Receivable
Schedules Of Concentration Of Risk By Risk Factor [Text Block]
Summary of Equity Method Investment
Equity Method Investments [Text Block]
Contract with customer milestone method.
Geographical
Statement Geographical [Axis]
Geographical
Segment Geographical [Domain]
Japan [Member]
JAPAN
Europe [Member]
Europe [Member]
United States/Rest of World and China.
U.S./RoW and China [Member]
United States Rest Of World And China [Member]
Summary of License Revenue and Development Revenue Recognized under Agreement
Contract With Customer Milestone Method Table [Text Block]
Transaction Price Related to Consideration Received and Accounts Receivable Allocated to Performance Obligations along with Associated Deferred Revenue and Product Revenue Net
Disaggregation Of Revenue Table [Text Block]
Roll-forward of Related Contract Liabilities
Contract With Customer Asset And Liability Table [Text Block]
Schedule of drug product revenue.
Schedule of Drug Product Revenue
Schedule Of Drug Product Revenue Table [Text Block]
Fair Values of Financial Assets Measured on Recurring Basis
Fair Value Assets Measured On Recurring Basis [Text Block]
Fair Values of Financial Liabilities Carried at Historical Cost
Fair Value Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]
Schedule of lease assets and related lease liabilities.
Schedule of Lease Assets and Related Lease Liabilities
Schedule Of Lease Assets And Related Lease Liabilities Table [Text Block]
Components of Lease Expense
Lease Cost Table [Text Block]
Schedule of supplemental cash flow information related to leases.
Schedule of Supplemental Cash Flow Information Related to Leases
Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]
Schedule of lease term and discount rate.
Schedule of Lease Term and Discount Rate
Schedule Of Lease Term And Discount Rate Table [Text Block]
Schedule of maturities of finance and operating leases liabilities.
Schedule of Maturities of Finance and Operating Leases Liabilities
Schedule Of Maturities Of Finance And Operating Leases Liabilities Table [Text Block]
Schedule of Cash and Cash Equivalents
Schedule Of Cash And Cash Equivalents Table [Text Block]
Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments
Schedule Of Available For Sale Securities Reconciliation Table [Text Block]
Summary of Contractual Maturities of Available-for-Sale Investments
Investments Classified By Contractual Maturity Date Table [Text Block]
Schedule of Inventory
Schedule Of Inventory Current Table [Text Block]
Schedule of Prepaid Expenses and Other Current Assets
Deferred Costs Capitalized Prepaid And Other Assets Disclosure [Text Block]
Schedule of Property and Equipment
Property Plant And Equipment [Text Block]
Schedule of Accrued and Other Current Liabilities
Schedule Of Accrued Liabilities Table [Text Block]
Schedule of Other Long-term Liabilities
Other Noncurrent Liabilities Table [Text Block]
Summary of Unconditional Purchase Obligations
Recorded Unconditional Purchase Obligations [Text Block]
Schedule of shares of common stock reserved for future issuance.
Summary of Common Stock Reserved for Future Issuance
Schedule Of Shares Of Common Stock Reserved For Future Issuance Table [Text Block]
Summary of Stock Option Transactions
Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]
Summary of RSU Activity
Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]
Schedule of Recorded Stock-Based Compensation Expense
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]
Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.
Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans
Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]
Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]
Schedule of income loss before income tax domestic and foreign.
Schedule of Components of Loss Before Income Taxes
Schedule Of Income Loss Before Income Tax Domestic And Foreign Table [Text Block]
Schedule of Components of Provision For Income Taxes
Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]
Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate
Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]
Schedule of Significant Components of Deferred Tax Assets
Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]
Schedule of Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits
Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]
Schedule of Revenue by Geographic Area
Revenue From External Customers By Geographic Areas Table [Text Block]
Inventory by geographic areas.
Schedule of Inventory by Geographic Area
Inventory By Geographic Areas Table [Text Block]
Schedule of Long Lived Assets by Geographic Area
Long Lived Assets By Geographic Areas Table [Text Block]
Summary of Finance and Operating Lease Right of Use Assets by Geographical Location.
Summary of Finance and Operating Lease Right of Use Assets by Geographical Location
Summary Of Finance And Operating Lease Right Of Use Assets By Geographical Location Table [Text Block]
Schedule of Customer Concentration by Collaboration Partners
Schedule Of Revenue By Major Customers By Reporting Segments Table [Text Block]
Accounting policy.
Accounting policy.
Accounting Policy [Table]
Accounting Policy [Table]
Concentration Risk Benchmark
Concentration Risk By Benchmark [Axis]
Concentration Risk Benchmark
Concentration Risk Benchmark [Domain]
Accounts receivable from distributors.
Accounts Receivable from Distributors [Member]
Accounts Receivable From Distributors [Member]
Concentration Risk Type
Concentration Risk By Type [Axis]
Concentration Risk Type
Concentration Risk Type [Domain]
Credit Concentration Risk [Member]
Credit Concentration Risk [Member]
Geographic Distribution
Geographic Distribution [Axis]
Geographic Distribution
Geographic Distribution [Domain]
Foreign subsidiaries [Member]
Geographic Distribution Foreign [Member]
Statistical Measurement
Range [Axis]
Statistical Measurement
Range [Member]
Minimum [Member]
Minimum [Member]
Maximum [Member]
Maximum [Member]
Long-Lived Tangible Asset
Property Plant And Equipment By Type [Axis]
Long-Lived Tangible Asset
Property Plant And Equipment Type [Domain]
Computer Equipment [Member]
Computer Equipment [Member]
Laboratory equipment.
Laboratory Equipment [Member]
Laboratory Equipment [Member]
Machinery [Member]
Machinery And Equipment [Member]
Furniture and Fixtures [Member]
Furniture And Fixtures [Member]
Initial Application Period Cumulative Effect Transition
Initial Application Period Cumulative Effect Transition [Axis]
Initial Application Period Cumulative Effect Transition
Initial Application Period Cumulative Effect Transition [Domain]
Impact of change in accounting principle upon adoption of ASU 2018-02.
Impact of change in accounting principle upon adoption of ASU 2018-02 [Member]
Impact Of Change In Accounting Principle Upon Adoption Of A S U201802 [Member]
Impact of change in accounting principle upon adoption of ASU 2016-01 [Member]
Difference Between Revenue Guidance In Effect Before And After Topic606 [Member]
Accounting Policy [Line Items]
Accounting Policy [Line Items]
Number of operating segment
Number Of Operating Segments
Currency translation adjustment
Translation Adjustment Functional To Reporting Currency Net Of Tax
Accounts Receivable [Member]
Accounts Receivable [Member]
Astra Zeneca agreements.
AstraZeneca Agreements [Member]
Astra Zeneca Agreements [Member]
Concentration risk, percentage
Concentration Risk Percentage1
Highly liquid investment maturity period.
Highly liquid investment maturity period
Highly Liquid Investment Maturity Period
Short term investments maximum maturity period.
Long term investments minimum maturity period.
Short term investments maturity
Short Term Investments Maximum Maturity Period
Long term Investments Maturity
Long Term Investments Minimum Maturity Period
Property and equipment estimated useful life
Property Plant And Equipment Useful Life
Impairment of long-lived assets
Impairment Of Long Lived Assets To Be Disposed Of
Amount constrained related to drug product shipment
Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
Description of payment term
Revenue Performance Obligation Description Of Payment Terms
Description of sales return.
Description of sales return
Description Of Sales Return
Acquisition and variable interest entity line items.
Acquisition and variable interest entity table.
Acquisition And Variable Interest Entity [Table]
Acquisition And Variable Interest Entity [Table]
Business Acquisition
Business Acquisition [Axis]
Business Acquisition, Acquiree
Business Acquisition Acquiree [Domain]
Beijing Kangda Yongfu Pharmaceutical Co., LTD.
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member]
Beijing Kangda Yongfu Pharmaceutical Co L T D [Member]
Related Party
Related Party Transactions By Related Party [Axis]
Related Party
Related Party [Domain]
FibroGen Beijing.
FibroGen Beijing [Member]
Fibro Gen Beijing [Member]
Finite-Lived Intangible Assets by Major Class
Finite Lived Intangible Assets By Major Class [Axis]
Finite-Lived Intangible Assets, Major Class Name
Finite Lived Intangible Assets Major Class Name [Domain]
Acquired license.
Acquired License [Member]
Acquired License [Member]
Equity Method Investment, Nonconsolidated Investee
Equity Method Investment Nonconsolidated Investee [Axis]
Equity Method Investment, Nonconsolidated Investee
Equity Method Investment Nonconsolidated Investee [Domain]
Beijing Falikang Pharmaceutical Co. Ltd.
Beijing Falikang Pharmaceutical Co. Ltd [Member]
Beijing Falikang Pharmaceutical Co Ltd [Member]
AstraZeneca AB.
AstraZeneca AB [Member]
Astra Zeneca A B [Member]
Counterparty Name
Counterparty Name [Axis]
Counterparty Name
Repurchase Agreement Counterparty Name [Domain]
Variable Interest Entity, Not Primary Beneficiary [Member]
Variable Interest Entity Not Primary Beneficiary [Member]
Acquisition And Variable Interest Entity [Line Items]
Acquisition And Variable Interest Entity [Line Items]
Percentage of outstanding shares acquired
Business Acquisition Percentage Of Voting Interests Acquired
Cash consideration
Payments To Acquire Businesses Gross
Transaction costs
Business Acquisition Cost Of Acquired Entity Transaction Costs
Acquisition costs
Business Combination Acquisition Related Costs
Entire purchase price
Business Combination Consideration Transferred1
Percentage of outstanding shares of acquiree sold by acquirer.
Percentage of outstanding shares sold in exchange for cash consideration
Percentage Of Outstanding Shares Of Acquiree Sold By Acquirer
Cash consideration for exchange of outstanding shares
Equity Method Investment Sold Carrying Amount
Percentage of outstanding shares owned
Variable Interest Entity Ownership Percentage
Falikang's total registered capital
Capital
Equity method investment additions.
Investment
Equity Method Investment Additions
Equity method investment increase (decrease) from currency translation.
Ownership Percentage
Equity Method Investment Ownership Percentage
Beginning balance
Equity Method Investments
Additions
Share of Net Loss
Income Loss From Equity Method Investments
Currency Translation
Equity Method Investment Increase Decrease From Currency Translation
Ending balance
Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.
Represents the amount of milestone payments related to commercial sales under the collaborative agreement.
The amount of additional consideration based on net sales of product as defined under a collaboration agreement.
Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.
Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Research and Development Arrangement, Contract to Perform for Others, Type
Research And Development Arrangement Contract To Perform For Others By Type [Axis]
Research and Development Arrangement, Contract to Perform for Others, Type
Research And Development Arrangement Contract To Perform For Others Type [Domain]
Clinical development milestone.
Clinical and Development Milestone [Member]
Clinical Development Milestones [Member]
Regulatory milestone.
Regulatory Milestone [Member]
Regulatory Milestones [Member]
SEC Schedule, 12-09, Valuation Allowances and Reserves Type
Valuation Allowances And Reserves Type [Axis]
SEC Schedule, 12-09, Valuation Allowances and Reserves
Valuation Allowances And Reserves [Domain]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront, non-contingent and time-based payments received
Proceeds From Upfront Non Contingent And Time Based Payments
Potential milestone payments
Potential Milestones
Commercial sales milestone
Commercial Sales Milestone
Additional consideration based on net sales description
Additional Consideration Based On Net Sales
Aggregate considerations received excluding drug product revenue
Collaborative Arrangement Aggregate Consideration Excluding Drug Product Revenue
Transaction price allocated to performance obligations.
Transaction price and allocated to performance obligations
Transaction Price Allocated To Performance Obligations
Consideration associated with milestone included in transaction price
Other Significant Noncash Transaction Value Of Consideration Given1
Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.
Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.
Development and regulatory approval milestones
Development And Regulatory Approval Milestones
Percentage of joint development costs committed to fund
Percentage Of Funding For Costs
Revenue during period from performance obligations
Revenue Remaining Performance Obligation
Unbilled contract asset
Supplies
Milestone payment received
Contract With Customer Liability Revenue Recognized
Estimated joint development extended service period.
Estimated joint development extended service period
Estimated Joint Development Extended Service Period
Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.
United states and rest of world.
U.S./RoW [Member]
United States And Rest Of World [Member]
Deferred approval milestone.
Deferred Approval Milestone [Member]
Deferred Approval Milestone [Member]
U.S./RoW [Member]
Legal Entity
Legal Entity [Axis]
Entity
Entity [Domain]
FibroGen, Inc.
FibroGen, Inc. [Member]
Fibro Gen Inc [Member]
China [Member]
CHINA
Balance Sheet Location
Balance Sheet Location [Axis]
Balance Sheet Location
Balance Sheet Location [Domain]
Other Noncurrent Liabilities
Other Noncurrent Liabilities [Member]
Accounts Payable [Member]
Accounts Payable [Member]
Accrued Liabilities [Member]
Accrued Liabilities [Member]
Income Statement Location
Income Statement Location [Axis]
Income Statement Location
Income Statement Location [Domain]
Selling, General and Administrative Expenses [Member]
Selling General And Administrative Expenses [Member]
Accrued and other current liabilities.
Accrued and Other Current Liabilities [Member]
Accrued And Other Current Liabilities [Member]
Upfront, non-contingent, non-refundable and time-based payments
Proceeds From Upfront Non Contingent Non Refundable And Time Based Payments
Represents the total amount of development costs that will be shared under collaborative agreement.
Shared development costs
Shared Development Costs
Drug product revenue
Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.
Commercial sales and other events milestone.
Amount of aggregate consideration receivable under collaborative arrangement.
Proceeds from upfront, non-contingent and non-refundable payments
Proceeds From Upfront Non Contingent And Non Refundable Payments
Commercial sales and other events milestone
Commercial Sales And Other Events Milestone
Aggregate considerations received
Collaborative Arrangement Aggregate Consideration
Contract with customer liability, milestone method revenue recognized.
Milestone payment, revenue recognition
Contract With Customer Liability Milestone Method Revenue Recognized
Historical co-promotion costs.
Co-promotion expenses.
Reversal of accrued co-promotion expenses.
Accrued long term co promotion liability non current.
Accrued long term co promotion liability current.
Historical co-promotion costs
Historical Co Promotion Costs
Reversal of accrued co-promotion expenses
Reversal Of Accrued Co Promotion Expenses
Co-promotion expenses
Co Promotion Expenses
Accrued long-term co-promotion expenses
Accrued Long Term Co Promotion Liability Non Current
Accrued long term co promotion liability current
Accrued Long Term Co Promotion Liability Current
Represents the amount of non-contingent upfront payments included under the collaborative agreement as arrangement consideration.
Variable consideration payment received upon achievement of milestone.
Variable consideration payment received related to co-development billings.
Measurement Input Type
Measurement Input Type [Axis]
Measurement Input Type
Measurement Input Type [Domain]
Measurement Input Discount Rate [Member]
Measurement Input Discount Rate [Member]
Valuation Approach and Technique
Valuation Technique [Axis]
Valuation Approach and Technique
Valuation Technique [Domain]
Discounted Cash Flow [Member]
Valuation Technique Discounted Cash Flow [Member]
Non-contingent upfront payments received
Proceeds From Non Contingent Upfront Payments
Variable consideration related to payments for milestones considered probable of being achieved
Variable Consideration Payment Received Upon Achievement Of Milestone
Variable consideration related to co-development billings
Variable Consideration Payment Received Related To Co Development Billings
Discount rate applied
Alternative Investment Measurement Input
Provision for co-development services.
Co-development services, estimated continuation year.
Co-development services, currently estimated continuation year
Co Development Services Estimated Continuation Year
Provision for co-development services
Provision For Co Development Services
Variable consideration related to profit share.
United states and rest of world and china.
U.S./RoW and China [Member]
United States And Rest Of World And China [Member]
Variable consideration related to profit share
Variable Consideration Related To Profit Share
Implied royalty rate used to find the net present value of future cash flows.
Royalty rate against projected net revenues
Royalty Rate On Net Revenue
Revenue Recognition Multiple Deliverable Arrangements [Table]
Revenue Recognition Multiple Deliverable Arrangements [Table]
Development Revenue [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Revenue Recognition Multiple Deliverable Arrangements [Line Items]
The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.
Co development information sharing and committee services.
Co-development, information sharing & committee services [Member]
Co Development Information Sharing And Committee Services [Member]
China performance obligation.
China performance obligation [Member]
China Performance Obligation [Member]
Cumulative Revenue
Cumulative Revenue License And Development Revenue Recognized
Deferred Revenue
Contract With Customer Liability
Total Consideration
Cash Consideration Received Under Collaboration Agreement
Variable consideration payment received from estimated future co-development billing.
Changes in revenue due to prior period adjustment of performance obligations
Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
Transaction price, variable consideration from estimated future co-development billing
Variable Consideration Payment Received From Estimated Future Co Development Billing
Supplies, net.
Deferred revenue
Deferred revenue
Net unbilled co-development revenue
Supplies Net
Revenue gross from contract with customer excluding assessed tax.
Disaggregation Of Revenue [Abstract]
Disaggregation Of Revenue [Table]
Disaggregation Of Revenue [Table]
Product [Member]
Price adjustment.
Price Adjustment [Member]
Price Adjustment [Member]
Non-key account hospital listing award.
Non-key Account Hospital Listing Award [Member]
Non Key Account Hospital Listing Award [Member]
Contractual sales rebate.
Contractual Sales Rebate [Member]
Contractual Sales Rebate [Member]
Other discounts and rebates.
Other Discounts and Rebates [Member]
Other Discounts And Rebates [Member]
Sales Return [Member]
Sales Returns And Allowances [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation Of Revenue [Line Items]
Gross revenue
Revenue Gross From Contract With Customer Excluding Assessed Tax
Rebates and discounts.
Rebates and Discounts [Member]
Rebates And Discounts [Member]
Gross accounts receivable.
Gross Accounts Receivable [Member]
Gross Accounts Receivable [Member]
Contract liabilities,
Contract Liabilities [Member]
Contract Liabilities [Member]
Contract with customer liability additions.
Contract with customer liability deduction.
Contract with customer, liability, increase (decrease) from current translation and other.
Contract with customer liability gross.
Contract with customer liability net of accounts receivable.
Contract with customer liability.
Contract With Customer Liability [Table]
Contract With Customer Liability [Table]
Contract With Customer Liability [Table]
Contract with Customer Liability [Line Items]
Contract With Customer Liability [Line Items]
Balance at December 31, 2019
Additions
Contract With Customer Liability Additions
Deduction
Contract With Customer Liability Deduction
Currency Translation and Other
Contract With Customer Liability Increase Decrease From Current Translation And Other
Gross Contract Liabilities Balance
Contract With Customer Liability Gross
Balance Presented Net Against Accounts Receivable
Contract With Customer Liability Net Of Accounts Receivable
Balance at December 31, 2020
Reductions to gross accounts receivable
Allowance For Doubtful Accounts Receivable
Astellas agreement.
Astellas Agreement
Astellas Agreement [Member]
Transaction Type
Transaction Type [Axis]
Transaction
Transaction [Domain]
API shipment.
API Shipment [Member]
A P I Shipment [Member]
Drug product revenue recognized
Estimated variable consideration transaction price.
Estimated variable consideration transaction price
Estimated Variable Consideration Transaction Price
Contract with Customer, Liability [Abstract]
Contract With Customer Liability [Abstract]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Measurement Frequency
Fair Value By Measurement Frequency [Axis]
Measurement Frequency
Fair Value Measurement Frequency [Domain]
Fair Value, Measurements, Recurring [Member]
Fair Value Measurements Recurring [Member]
Fair Value Hierarchy and NAV
Fair Value By Fair Value Hierarchy Level [Axis]
Fair Value Hierarchy and NAV
Fair Value Measurements Fair Value Hierarchy [Domain]
Level 1 [Member]
Fair Value Inputs Level1 [Member]
Level 2 [Member]
Fair Value Inputs Level2 [Member]
Level 3 [Member]
Fair Value Inputs Level3 [Member]
Investment Type
Investment Type [Axis]
Investments
Investment Type Categorization [Member]
US treasury notes and bills [Member]
U S Treasury Securities [Member]
Bond and mutual funds.
Bond and mutual funds [Member]
Bond And Mutual Funds [Member]
Equity investments [Member]
Equity Securities [Member]
Money market funds [Member]
Money Market Funds [Member]
Certificate of deposit [Member]
Certificates Of Deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Investments
Available For Sale Securities
Assets fair value disclosure
Cash And Cash Equivalents Fair Value Disclosure
Total fair value of financial assets
Assets Fair Value Disclosure
Transfers of assets from level 1 to 2
Fair Value Assets Level1 To Level2 Transfers Amount
Transfers of assets from level 2 to 1
Fair Value Assets Level2 To Level1 Transfers Amount
Transfers of assets into level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
Transfers of assets out of level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
Liability Class
Fair Value By Liability Class [Axis]
Fair Value by Liability Class
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]
Lease obligations.
Lease obligations [Member]
Lease Obligations [Member]
Liabilities fair value disclosure
Liabilities Fair Value Disclosure
Transfers of liabilities from level 1 to 2
Fair Value Liabilities Level1 To Level2 Transfers Amount
Transfers of liabilities from level 2 to 1
Fair Value Liabilities Level2 To Level1 Transfers Amount
Transfers of liabilities into level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
Transfers of liabilities out of level 3
Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
Number of finance leases.
Lessee Lease Description [Table]
Lessee Lease Description [Table]
Building [Member]
Building [Member]
Shorenstein properties LLC.
Shorenstein Properties LLC [Member]
Shorenstein Properties L L C [Member]
Beijing economic-technological development area.
Beijing Economic-Technological Development Area [Member]
Beijing Economic Technological Development Area [Member]
Office spaces.
Office Spaces [Member]
Office Spaces [Member]
Office Equipment [Member]
Office Equipment [Member]
Lessee Lease Description [Line Items]
Lessee Lease Description [Line Items]
Number of finance leases
Number Of Finance Leases
Lessee, finance lease, expiration period.
Lessee, finance lease, option to extend the additional lease term.
Lessee, finance lease, additional lease expiration period.
Percentage increases on each anniversary of rent commencement date.
Lessee, finance lease, initial lease term
Lessee Finance Lease Term Of Contract1
Lessee, finance lease, expiration period
Lessee Finance Lease Expiration Period
Lessee, finance lease, option to extend the additional lease term
Lessee Finance Lease Option To Extend Additional Lease Term
Lessee, finance lease, additional lease expiration period
Lessee Finance Lease Additional Lease Expiration Period
Percentage increases on each anniversary of rent commencement date
Percentage Increases On Each Anniversary Of Rent Commencement Date
Lessee, finance lease, existence of option to extend
Lessee Finance Lease Existence Of Option To Extend
Lessee, finance lease, option to extend
Lessee Finance Lease Option To Extend
Number of operating leases.
Lessee, operating lease, expiration period.
Number of operating leases
Number Of Operating Leases
Lessee, operating lease, lease term
Lessee Operating Lease Term Of Contract
Lessee, operating lease, expiration period
Lessee Operating Lease Expiration Period
Finance lease, right-of-use assets - cost.
Finance lease accumulated amortization.
Operating lease, right-of-use assets - cost.
Operating lease, accumulated amortization.
Finance lease and operating lease assets.
Finance lease and operating lease liability.
Right-of-use assets - cost
Finance Lease Right Of Use Assets Cost
Accumulated amortization
Finance Lease Accumulated Amortization
Finance lease right-of-use assets, net
Right-of-use assets - cost
Operating Lease Right Of Use Assets Cost
Accumulated amortization
Operating Lease Accumulated Amortization
Operating lease right-of-use assets, net
Operating Lease Right Of Use Asset
Total lease assets
Finance Lease And Operating Lease Assets
Finance lease liabilities
Operating lease liabilities
Operating Lease Liability Current
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]
Operating Lease Liability Current Statement Of Financial Position Extensible List
Finance lease liabilities
Operating lease liabilities
Operating Lease Liability Noncurrent
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]
Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
Total lease liabilities
Finance Lease And Operating Lease Liability
Finance lease cost:
Lease Cost [Abstract]
Amortization of right-of-use assets
Interest on lease liabilities
Finance Lease Interest Expense
Operating lease cost
Operating Lease Cost
Sublease income
Sublease Income
Total lease cost
Lease Cost
Cash paid for amounts included in the measurement of lease liabilities.
Right-of-use assets obtained in exchange for new lease liabilities.
Cash paid for amounts included in the measurement of lease liabilities:
Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]
Operating cash flows from operating leases
Operating Lease Payments
Operating cash flows from finance leases
Finance Lease Interest Payment On Liability
Financing cash flows from finance leases
Right-of-use assets obtained in exchange for new lease liabilities:
Right Of Use Assets Obtained In Exchange For New Lease Liabilities [Abstract]
Finance leases
Right Of Use Asset Obtained In Exchange For Finance Lease Liability
Operating leases
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
Weighted-average remaining lease term.
Weighted-average discount rate.
Weighted-average remaining lease term (years):
Weighted Average Remaining Lease Term [Abstract]
Finance leases
Finance Lease Weighted Average Remaining Lease Term1
Operating leases
Operating Lease Weighted Average Remaining Lease Term1
Weighted-average discount rate:
Weighted Average Discount Rate [Abstract]
Finance leases
Finance Lease Weighted Average Discount Rate Percent
Operating leases
Operating Lease Weighted Average Discount Rate Percent
Finance Leases
Finance Lease Liabilities Payments Due [Abstract]
2021
Finance Lease Liability Payments Due Next Twelve Months
2022
Finance Lease Liability Payments Due Year Two
2023
Finance Lease Liability Payments Due Year Three
Total future lease payments
Finance Lease Liability Payments Due
Less: Interest
Finance Lease Liability Undiscounted Excess Amount
Present value of lease liabilities
Finance Lease Liability
Operating Leases
Operating Lease Liabilities Payments Due [Abstract]
2021
Lessee Operating Lease Liability Payments Due Next Twelve Months
2022
Lessee Operating Lease Liability Payments Due Year Two
2023
Lessee Operating Lease Liability Payments Due Year Three
Total future lease payments
Lessee Operating Lease Liability Payments Due
Less: Interest
Lessee Operating Lease Liability Undiscounted Excess Amount
Present value of lease liabilities
Operating Lease Liability
Cash And Cash Equivalents [Abstract]
Cash
Cash
Money market funds
Money Market Funds At Carrying Value
Total cash and cash equivalents
Accrued Liabilities Current [Abstract]
Schedule Of Available For Sale Securities [Table]
Schedule Of Available For Sale Securities [Table]
U.S. treasury notes and bills [Member]
Schedule of Available-for-sale Securities [Line Items]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost
Available For Sale Securities Amortized Cost
Gross Unrealized Holding Gains
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
Gross Unrealized Holding Losses
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
Fair Value
Available for sale securities bond and mutual funds maturing within one year.
Available For Sale Securities Debt Maturities [Abstract]
Within one year - Bond and mutual funds
Available For Sale Securities Bond And Mutual Funds Maturing Within One Year
Equity investments
Available For Sale Securities Equity Securities
Total investments
Schedule Of Investments [Abstract]
Other-than-temporary impairment loss
Other Than Temporary Impairment Losses Investments Availableforsale Securities
Raw materials
Inventory Raw Materials
Work-in-progress
Inventory Work In Process
Finished goods
Inventory Finished Goods
Total inventories
Percentage of pre-launch inventory capitalized of aggregate inventory balance.
Percentage of pre-launch inventory capitalized of aggregate inventory balance
Percentage Of Pre Launch Inventory Capitalized Of Aggregate Inventory Balance
Prepaid Expense And Other Assets Current [Abstract]
Unbilled contract assets
Deferred revenues from associated contracts
Net unbilled contract assets
Prepaid assets
Prepaid Expense Current
Other current assets
Other Assets Current
Total prepaid expenses and other current assets
Number of regulatory milestones.
Number of regulatory milestones
Number Of Regulatory Milestones
Property Plant And Equipment [Abstract]
Schedule Of Property Plant And Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Leasehold improvements [Member]
Leasehold Improvements [Member]
Construction in progress [Member]
Construction In Progress [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment [Line Items]
Property and equipment, gross
Property Plant And Equipment Gross
Less: accumulated depreciation
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Property and equipment, net
Depreciation expense
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Accrued active pharmaceutical ingredient product price adjustment current.
Accrued contract liabilities to pharmaceutical distributors current.
Accrued co-promotion expenses - current.
Accrued profit share current.
Property taxes and other current.
Preclinical and clinical trial accruals
Accrued Preclinical And Clinical Trial Current
API product price adjustment
Accrued Active Pharmaceutical Ingredient Product Price Adjustment Current
Payroll and related accruals
Employee Related Liabilities Current
Contract liabilities to pharmaceutical distributors
Accrued Contract Liabilities To Pharmaceutical Distributors Current
Accrued co-promotion expenses - current
Accrued Co Promotion Expenses Current
Roxadustat profit share to AstraZeneca
Accrued Profit Share Current
Property taxes and other
Property Taxes And Other Current
Professional services
Accrued Professional Fees Current
Other
Other Accrued Liabilities Current
Total accrued and other current liabilities
Accrued Liabilities Current
API product price change in estimated variable consideration
Profit share liability
Other Liabilities Noncurrent [Abstract]
Other long-term tax liabilities
Deferred Tax And Other Liabilities Noncurrent
Operating lease liabilities, non-current
Other
Other Sundry Liabilities Noncurrent
Total other long-term liabilities
Accrued long-term co-promotional liability non current.
Reversal of previously accrued long term co promotion expenses.
Accrued long-term co-promotional expenses
Accrued Long Term Co Promotional Liability Non Current
Reversal of previously accrued long-term co-promotion expenses
Reversal Of Previously Accrued Long Term Co Promotion Expenses
Number of product development obligations.
Debt Instrument [Table]
Debt Instrument [Table]
Variable Rate
Variable Rate [Axis]
Variable Rate
Variable Rate [Domain]
Bank of Finland interest rate.
Bank of Finland Interest Rate [Member]
Bank Of Finland Interest Rate [Member]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Number of product development obligations
Number Of Product Development Obligations
Percentage points deducted to reference rate to compute effective interest rate
Loans Receivable Basis Spread On Variable Rate
Interest rate on product development advances
Debt Instrument Interest Rate Stated Percentage
Accrued Product Development Costs Excluding Interest.
Accrued product development costs excluding interest
Accrued Product Development Costs Excluding Interest
Accrued Interest
Interest Payable Current And Noncurrent
Commitments and contingencies.
Commitments and contingencies.
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Category of Item Purchased
Long Term Purchase Commitment By Category Of Item Purchased [Axis]
Long-term Purchase Commitment, Category of Item Purchased
Long Term Purchase Commitment Category Of Item Purchased [Domain]
Research and pre-clinical stage development programs.
Research and Pre-Clinical Stage Development Programs [Member]
Research And Pre Clinical Stage Development Programs [Member]
Commitments And Contingencies [Line Items]
Commitments And Contingencies [Line Items]
Outstanding non-cancelable contract obligations
Contractual Obligation
Unconditional Purchase Obligations Excluding Capital Stock Redemptions [Abstract]
Recorded Unconditional Purchase Obligation [Table]
Recorded Unconditional Purchase Obligation [Table]
Manufacture and Supply of Roxadustat.
Manufacture and Supply of Roxadustat [Member]
Manufacture And Supply Of Roxadustat [Member]
Manufacture and supply of pamrevlumab.
Manufacture and Supply of Pamrevlumab [Member]
Manufacture And Supply Of Pamrevlumab [Member]
Other Purchases.
Other Purchases [Member]
Other Purchases [Member]
Recorded Unconditional Purchase Obligation [Line Items]
Recorded Unconditional Purchase Obligation [Line Items]
Purchase obligations due 2021
Recorded Unconditional Purchase Obligation Due Within One Year
Purchase obligations due 2022
Recorded Unconditional Purchase Obligation Due In Second Year
Total purchase obligations
Recorded Unconditional Purchase Obligation
Maximum future milestone payments.
Maximum future milestone payments
Maximum Future Milestone Payments
Shareholders equity and stock-based compensation.
Shareholders Equity And Stock Based Compensation [Abstract]
Schedule Of Stock By Class [Table]
Schedule Of Stock By Class [Table]
Fibro Gen Europe Oy.
FibroGen Europe [Member]
Fibrogen Europe Oy [Member]
Class of Stock
Statement Class Of Stock [Axis]
Class of Stock
Class Of Stock [Domain]
Series A [Member]
Series A Preferred Stock [Member]
Series B [Member]
Series B Preferred Stock [Member]
Series C [Member]
Series C Preferred Stock [Member]
Series D [Member]
Series D Preferred Stock [Member]
Series E [Member]
Series E Preferred Stock [Member]
Series F [Member]
Series F Preferred Stock [Member]
Series G [Member]
Series G Preferred Stock [Member]
Series H [Member]
Series H Preferred Stock [Member]
FibroGen Cayman.
FibroGen Cayman [Member]
Fibro Gen Cayman [Member]
Sale of Stock
Subsidiary Sale Of Stock [Axis]
Sale of Stock
Sale Of Stock Name Of Transaction [Domain]
IPO [Member]
I P O [Member]
Class Of Stock [Line Items]
Class Of Stock [Line Items]
Required minimum shareholder percentage to call for redemption of preferred shares.
Preferred stock redemption percentage
Preferred Stock Redemption Terms
Minimum percentage of shareholder's approval to call for redemption of preferred shares
Required Minimum Shareholder Percentage To Call For Redemption Of Preferred Shares
Preferred stock, voting rights
Preferred Stock Voting Rights
Conversion rights, shares issued upon conversion of each preferred share
Convertible Preferred Stock Shares Issued Upon Conversion
Preferred shares issued, price per share.
Preferred shares issued, price per share
Preferred Shares Issued Price Per Share
Cash dividend percentage
Preferred Stock Dividend Rate Percentage
Equity [Abstract]
Common stock voting rights
Common Stock Voting Rights
Common stock shares reserved.
ESPP [Member]
Employee Stock [Member]
Common stock outstanding
Stock options outstanding
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
RSUs outstanding
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
Shares reserved for future stock options and RSUs grant
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
Shares reserved for future ESPP offering
Common Stock Capital Shares Reserved For Future Issuance
Total shares of common stock reserved
Common Stock Shares Reserved
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Plan Name
Plan Name [Axis]
Plan Name
Plan Name [Domain]
Two thousand and five stock plan.
2005 Stock Plan
Two Thousand And Five Stock Plan [Member]
Two thousand and fourteen equity incentive plan.
2014 Equity Incentive Plan
Two Thousand And Fourteen Equity Incentive Plan [Member]
Vesting
Vesting [Axis]
Vesting
Vesting [Domain]
First Anniversary [Member]
Share Based Compensation Award Tranche One [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period of stock options
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
Expiration period of stock options
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
Termination date of equity incentive plan
Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
Option vesting term
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
Percentage of fair value exercise price grant date
Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
Percentage of vesting rights
Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
Number of common stock reserved for issuance
Common stock reserved for future issuance, Description
Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period Description
Percentage of common stock reserved for future issuance
Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
Number of common stock repurchased
Stock Repurchased During Period Shares
Stock issued during period shares stock options exercised full year.
Outstanding, Beginning Balance, Shares
Granted, Shares
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Exercised, Shares
Stock Issued During Period Shares Stock Options Exercised Full Year
Expired, Shares
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
Forfeited, Shares
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
Outstanding, Ending Balance, Shares
Vested and expected to vest, Shares
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
Exercisable, Shares
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Outstanding, Beginning Balance, Weighted Average Exercise per Share
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Granted, Weighted Average Exercise per Share
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Exercised, Weighted Average Exercise per Share
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
Expired, Weighted Average Exercise per Share
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
Forfeited, Weighted Average Exercise per Share
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
Outstanding, Ending Balance, Weighted Average Exercise per Share
Vested and expected to vest, Weighted Average Exercise per Share
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
Exercisable, Weighted Average Exercise per Share
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Outstanding, Weighted Average Remaining Contractual Life
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
Vested and expected to vest, Weighted Average Remaining Contractual Life
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
Exercisable, Weighted Average Remaining Contractual Life
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
Outstanding, Aggregate Intrinsic Value
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
Vested and expected to vest, Aggregate Intrinsic Value
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
Exercisable, Aggregate Intrinsic Value
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
Total intrinsic value of options exercised
Award Type
Award Type [Axis]
Award Type
Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]
Restricted Stock Unit [Member]
Restricted Stock Units R S U [Member]
Unvested, Shares, Beginning Balance
Granted, Shares
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
Vested, Shares
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
Forfeited, Shares
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
Unvested, Shares, Ending Balance
Unvested, Fair value at Grant, Beginning Balance
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
Granted, Fair value at Grant
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
Vested, Fair value at Grant
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
Forfeited, Fair value at Grant
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
Unvested, Fair value at Grant, Ending Balance
RSUs released and issued net of shares withheld for taxes
Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
Weighted-average fair value of awards granted
Two thousand and fourteen employee stock purchase plan.
2014 ESPP [Member]
Two Thousand And Fourteen Employee Stock Purchase Plan [Member]
Purchase of common stock shares at discount
Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Purchase Date
Percentage of fair value exercise price grant date
Percentage of common stock reserved for future issuance
Increase in number of shares of common stock reserved for future issuance, shares
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
Shares purchased by employees
Stock Issued During Period Shares Employee Stock Purchase Plans
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Research and development [Member]
Research And Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense
Allocated Share Based Compensation Expense
Employee stock options [Member]
Employee Stock Option [Member]
Employee stock purchase plans [Member]
Stock Compensation Plan [Member]
Expected term (in years)
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
Expected volatility
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
Expected volatility, minimum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
Expected volatility, maximum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
Risk-free interest rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
Risk-free interest rate, minimum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
Risk-free interest rate, maximum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
Expected dividend yield
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
Weighted average estimated fair value
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
Stock option awards.
Stock Option Awards [Member]
Stock Option Awards [Member]
Unrecognized compensation costs
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
Non-vested stock option awards granted that will be recognized on a straight-line basis over the weighted-average period
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
Unrecognized compensation costs
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
Class of warrant or right number of warrants or rights exercised during period.
Warrants to purchase common stock exercised
Class Of Warrant Or Right Number Of Warrants Or Rights Exercised During Period
Warrants to purchase common stock outstanding
Class Of Warrant Or Right Outstanding
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Antidilutive Securities
Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]
Antidilutive Securities, Name
Antidilutive Securities Name [Domain]
RSUs [Member]
Warrants [Member]
Warrant [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of net loss per share
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Defined contribution plan, maximum annual contributions per employee, percent
Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
Defined contribution plan, employer matching contributions
Defined Contribution Plan Cost Recognized
Components Of Income Tax Expense Benefit Continuing Operations [Abstract]
Domestic
Income Loss From Continuing Operations Before Income Taxes Domestic
Foreign
Income Loss From Continuing Operations Before Income Taxes Foreign
Current:
Current Federal State And Local Tax Expense Benefit [Abstract]
Federal
Current Federal Tax Expense Benefit
State
Current State And Local Tax Expense Benefit
Foreign
Current Foreign Tax Expense Benefit
Total current
Current Income Tax Expense Benefit
Deferred:
Deferred Federal State And Local Tax Expense Benefit [Abstract]
Federal
Deferred Federal Income Tax Expense Benefit
State
Deferred State And Local Income Tax Expense Benefit
Foreign
Deferred Foreign Income Tax Expense Benefit
Total deferred
Deferred Income Tax Expense Benefit
Total provision for income taxes
Effective income tax rate reconciliation deduction expense share based compensation cost.
Effective income tax rate reconciliation benefit on intercompany transfer of assets.
Effective income tax rate reconciliation valuation allowance on intercompany transfer of assets.
Effective income tax rate reconciliation net operating losses not benefitted.
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]
Tax at statutory federal rate
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
State tax
Effective Income Tax Rate Reconciliation State And Local Income Taxes
Stock-based compensation expense
Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost
Benefit due to intercompany transfer of assets
Effective Income Tax Rate Reconciliation Benefit On Intercompany Transfer Of Assets
Valuation allowance on intercompany transfer of assets
Effective Income Tax Rate Reconciliation Valuation Allowance On Intercompany Transfer Of Assets
Net operating losses not benefitted
Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted
Foreign net operating losses not benefitted
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
Deduction limitation on executive compensation
Effective Income Tax Rate Reconciliation Deductions
Other
Effective Income Tax Rate Reconciliation Other Adjustments
Total
Effective Income Tax Rate Continuing Operations
Deferred tax assets intangible assets.
Deferred tax liabilities fixed assets.
Components Of Deferred Tax Assets And Liabilities [Abstract]
Federal and state net operating loss carryforwards
Deferred Tax Assets Operating Loss Carryforwards
Tax credit carryforwards
Deferred Tax Assets Tax Credit Carryforwards
Foreign net operating loss carryforwards
Deferred Tax Assets Operating Loss Carryforwards Foreign
Stock-based compensation
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
Lease obligations
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
Reserves and accruals
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
Deferred revenue
Deferred Tax Assets Deferred Income
Intangible assets
Deferred Tax Assets Intangible Assets
Other
Deferred Tax Assets Other
Subtotal
Deferred Tax Assets Gross
Less: Valuation allowance
Deferred Tax Assets Valuation Allowance
Net deferred tax assets
Deferred Tax Assets Net
Fixed assets
Deferred Tax Liabilities Fixed Assets
Other
Deferred Tax Liabilities Other
Net deferred tax liabilities
Deferred Tax Liabilities
Total net deferred tax assets
Deferred Tax Assets Liabilities Net
Income taxes line items.
Income taxes.
Income Taxes [Table]
Income Taxes [Table]
Income Tax Authority
Income Tax Authority [Axis]
Income Tax Authority
Income Tax Authority [Domain]
Foreign net operating loss [Member]
Foreign Country [Member]
Federal [Member]
Domestic Country [Member]
State [Member]
State And Local Jurisdiction [Member]
California [Member]
CALIFORNIA
Tax Period
Tax Period [Axis]
Tax Period
Tax Period [Domain]
Earliest Tax Year [Member]
Earliest Tax Year [Member]
Latest Tax Year [Member]
Latest Tax Year [Member]
Income Taxes [Line Items]
Income Taxes [Line Items]
Increase in valuation allowance
Valuation Allowance Deferred Tax Asset Change In Amount
Deferred tax asset for temporary difference
Deferred Tax Asset Intra Entity Transfer Asset Other Than Inventory
Operating loss carryforwards expiration year.
Operating loss carryforwards expiration year
Operating Loss Carryforwards Expiration Year
Other tax credit carryforwards expiration year.
Other tax credit carryforwards
Deferred Tax Assets Tax Credit Carryforwards Other
Other tax credit carryforwards expiration year
Other Tax Credit Carryforwards Expiration Year
Experience historical ownership changes.
Percentage of ownership changes
Experience Historical Ownership Changes
Unrecognized tax benefits
Unrecognized Tax Benefits
Accrued interest, unrecognized tax benefits
Unrecognized Tax Benefits Interest On Income Taxes Accrued
Unrecognized tax benefits that would affect effective tax rate
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
Income Tax Contingency [Table]
Income Tax Contingency [Table]
Federal and state.
Federal and State [Member]
Federal And State [Member]
Income Tax Contingency [Line Items]
Income Tax Contingency [Line Items]
Beginning balance
Increase due to prior positions
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
Decrease due to prior positions
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
Increase due to current year position
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
Ending Balance
Unrecognized tax benefits description
Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Estimated Range Not Possible
Foreign statute of limitation generally remains open in the year
Open Tax Year
Schedule Of Related Party Transactions By Related Party [Table]
Schedule Of Related Party Transactions By Related Party [Table]
License and development.
License and Development [Member]
License And Development [Member]
Astellas.
Astellas [Member]
Astellas [Member]
Collaborative Arrangement [Member]
Collaborative Arrangement [Member]
Falikang.
Falikang [Member]
Falikang [Member]
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
License and development revenue related to collaboration agreements
Revenue From Related Parties
Drug product revenue from related party.
Drug product revenue from a related party
Drug Product Revenue From Related Party
Expense related to collaboration agreements
Related Party Transaction Expenses From Transactions With Related Party
Deferred revenue
Net unbilled contract asset
Accrued liabilities and accounts payable to related party
Miscellaneous receivables.
Investment
Investment Income Net
Equity method investments
Miscellaneous receivables
Miscellaneous Receivables
Customer Concentration Risk [Member]
Customer Concentration Risk [Member]
Percentage of Revenue [Member]
Sales Revenue Net [Member]
Percentage of Accounts Receivable [Member]
Segment Reporting Disclosure Of Entitys Reportable Segments [Abstract]
Schedule Of Segment Reporting Information By Segment [Table]
Schedule Of Segment Reporting Information By Segment [Table]
All other.
All other [Member]
All Other [Member]
Segment Reporting Information [Line Items]
Segment Reporting Information [Line Items]
Revenue recognized
Revenues
United States [Member]
UNITED STATES
Total inventory
Schedule Of Revenues From External Customers And Long Lived Assets [Table]
Schedule Of Revenues From External Customers And Long Lived Assets [Table]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues From External Customers And Long Lived Assets [Line Items]
Total finance lease right-of-use assets
Total operating lease right-of-use assets
Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]
Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]
Percentage of Accounts Receivable [Member]
Astellas-Related party [Member]
AstraZeneca [Member]
Entity Wide Revenue Major Customer [Line Items]
Entity Wide Revenue Major Customer [Line Items]
Valuation And Qualifying Accounts Disclosure [Table]
Valuation And Qualifying Accounts Disclosure [Table]
Valuation Allowances for Deferred Tax Assets [Member]
Valuation Allowance Of Deferred Tax Assets [Member]
Valuation allowance for rebates and discounts.
Valuation Allowance for Rebates and Discounts [Member]
Valuation Allowance For Rebates And Discounts [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Year
Valuation Allowances And Reserves Balance
Charged (Credited) to Statement of Operation
Valuation Allowances And Reserves Charged To Cost And Expense
Charged to Other Accounts - Liabilities and Equity
Valuation Allowances And Reserves Charged To Other Accounts
Deductions, Net
Valuation Allowances And Reserves Deductions
Balance at End of Year